Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis - Wikidata - wikimedia - TriplyDB

Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis

Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis

http://www.wikidata.org/entity/Q35509695

about

Tumor immunotargeting using innovative radionuclides Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation Establishment and characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel Emerging trends for radioimmunotherapy in solid tumors Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects Molecular and cellular effects of Auger emitters: 2008-2011.General overview of radioimmunotherapy of solid tumors.Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers.Imaging the inside of a tumour: a review of radionuclide imaging and theranostics targeting intracellular epitopes.Uptake, internalization and nuclear translocation of radioimmunotherapeutic agents.Comparison of the radiotoxicity of the 99mTc-labeled compounds 99mTc-pertechnetate, 99mTc-HMPAO and 99mTc-MIBI.Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery.[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].Subcellular Targeting of Theranostic Radionuclides

P2860

Q28083230-39E0AA76-F2BA-4A3F-96DE-31EFB64E65AF Q33872675-69E7549A-1311-4AB6-8D1D-6DFBDA68763F Q34841141-86E99B44-87CF-4BD3-B145-96D4EDF5B221 Q34903258-B36A0CDD-0619-4B04-800F-849C8D9054F3 Q35861726-EBCA9F77-71A4-4A7F-95E0-48EC81A43881 Q35894296-05A68181-598D-4968-9CB1-62F63E1965F6 Q36336223-3619D821-AE62-4449-9C86-37603A00F86E Q37222795-5E09EDAF-E831-4985-BE83-3C2ED1AD7181 Q37267538-DFCC4EC4-CA13-4C43-BF8C-A823823C7289 Q38018374-DE5DA220-84B9-4A43-B999-FC1FB0AEF9C8 Q38103579-5562918E-0364-410F-9A2E-C43B18CA0D24 Q38149131-37EFCE15-168E-48E6-9276-E77F64625DD7 Q38176263-FE17124D-FEF5-4991-819F-B0E8629E53E2 Q38193173-9F327F26-945D-4C22-925C-7F1F8456A798 Q38775203-12A787BB-C350-4128-A52F-72F865D5CEF5 Q38834565-2C054CCF-CCFE-4774-8A42-E8DECFB1278B Q39009271-54AD7D98-D926-4E41-AACE-BF7D174E13A3 Q53500216-9F7FF555-F80A-4BA1-8624-CC1F98C257A0 Q54025029-A66713A8-84F4-45D3-BA15-C61355082D61 Q58764832-933EE936-29F2-4750-9A67-85DF3786DE67

P2860

Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis

http://www.wikidata.org/entity/Q35509695

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@ast

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@en

type

label

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@ast

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@en

prefLabel

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@ast

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@en

P1433

Q35509695-C9C8243E-90D0-4CD6-9FFD-14D534E9C90D

P1476

Q35509695-64272BFB-74FC-4546-9739-D26163D46AAF

P2093

Q35509695-0A00A763-6231-47BA-8D0B-87ABCFE6E781

Q35509695-0BE426BC-2170-460F-A862-267C28A2261B

Q35509695-2CDCBCDE-A1E8-4E31-B2E1-E22769D622A2

Q35509695-413A6F61-5FC4-4FB6-9002-88F1346EC7A5

Q35509695-480B280E-C977-4AD2-B521-7F8345781D83

Q35509695-A21F0EDD-C099-47F7-8B94-71EDC056E42A

Q35509695-B7F593DB-E86D-482F-9F0E-5FFDBF6C1EC5

Q35509695-C25D3190-0E12-441E-AB96-341630F9EBD9

Q35509695-D7B2D8F4-BEC4-419B-AE9A-953F99551037

Q35509695-DFC9BEAE-0254-4F8A-B8D6-678A1BFB898D

P2860

Q35509695-075F2DB4-1799-4DDD-9E25-9CCF8763EABB

Q35509695-0B64E3D1-B5EA-4CF1-8CF1-3136454E9812

Q35509695-112302B8-8C74-4AFC-B5C3-01160201B345

Q35509695-1AD84D93-DA70-466E-8FB6-E772D58214F9

Q35509695-1D7EDC65-5949-43F8-B090-5561A655EE3F

Q35509695-1E067771-10BB-4771-A704-103E7FDB04D8

Q35509695-2AE6B715-C460-4222-927C-3BC8084986F6

Q35509695-2DEF1B13-1F3D-410B-967C-00BD1D4F0994

Q35509695-33CBC17D-3740-408C-B9C0-655F5D8D0E65

Q35509695-45D6A807-B6E9-41C7-B2F1-F8D41C9BFFF2

P304

Q35509695-19711DE8-757B-4C10-AAB5-3D5BAA3DF659

P31

Q35509695-16A345C3-694E-498B-9CF9-005E5B58C54B

P356

Q35509695-BC047F0D-C25D-4C22-BA0F-B1E15C747613

P407

Q35509695-ABEF82A9-E14B-4EBB-9B06-C14E38363212

P433

Q35509695-78FD4631-A0C0-4216-AF46-D3B163739EC3

P478

Q35509695-0F971FD4-3023-42B2-B700-9A6A6B7A7085

P577

Q35509695-BDE7D631-1CD9-49B8-A35B-EE1FB78CBFB7

P5875

Q35509695-92C448E1-A1CE-4942-9A1A-F6936C7208EC

P698

Q35509695-4D173739-CC25-481F-BC8C-973E54BAC265

P932

Q35509695-3315F327-8087-4D72-8F08-69A3FC4B9314

P356

JNUMED.109.066993

P1433

The Journal of Nuclear Medicine

P1476

Noninternalizing monoclonal an ...... lume peritoneal carcinomatosis

@en

P2093

André Pèlegrin

http://www.w3.org/2001/XMLSchema#string

Caroline Bascoul-Mollevi

http://www.w3.org/2001/XMLSchema#string

Isabelle Navarro-Teulon

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Pouget

http://www.w3.org/2001/XMLSchema#string

Lore Santoro

http://www.w3.org/2001/XMLSchema#string

Monique Pèlegrin

http://www.w3.org/2001/XMLSchema#string

Pierre-Olivier Kotzki

http://www.w3.org/2001/XMLSchema#string

Samir Boutaleb

http://www.w3.org/2001/XMLSchema#string

Vincent Boudousq

http://www.w3.org/2001/XMLSchema#string

Véronique Garambois

http://www.w3.org/2001/XMLSchema#string

P2860

Random-effects models for longitudinal data

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer.

Biophysical aspects of Auger processes.

Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines.

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.

Radiobiologic principles in radionuclide therapy.

Radioimmunotherapy and colorectal cancer.

P304

2033-2041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.109.066993

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38086539

http://www.w3.org/2001/XMLSchema#string

P698

19910417

http://www.w3.org/2001/XMLSchema#string

P932

3206883

http://www.w3.org/2001/XMLSchema#string